SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (3445)10/28/2002 9:20:44 AM
From: William Partmann  Read Replies (1) | Respond to of 10345
 
Harold, I am not sure of the revenue prialt will produce when it is ok'd because of the manner of delivery. I believe it will be a small niche drug.

Regards



To: Harold Engstrom who wrote (3445)10/28/2002 9:49:55 AM
From: Icebrg  Read Replies (1) | Respond to of 10345
 
Harold

I agree fully with Bill on the subject of Prialt. It will most probably be a very limited market.

And to make things worse. Canadian NeuroMed is supposed to have an oral N-type calcium blocker under development. So, even if Prialt lives up to some of its expectations short-term, the product's longer term prospects don't seem too good.

Erik


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News